middle.news
Imagion Biosystems Advances MagSense HER2 Program, Eyes IND Filing in Q3 2025
4:25am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Imagion Biosystems Advances MagSense HER2 Program, Eyes IND Filing in Q3 2025
4:25am on Monday 2nd of June, 2025 AEST
Key Points
Progress on MagSense HER2 imaging agent manufacturing for Phase 2 study
Planned IND application filing with FDA in Q3 2025
Operating cash outflow increased to AU$0.959 million due to R&D ramp-up
Cash balance at AU$1.71 million with AU$10.78 million undrawn convertible note facility
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imagion Biosystems (ASX:IBX)
OPEN ARTICLE